TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06132490

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valveless Insufflator with 12 mmHg intra-abdominal pressure
Description: In this group valveless insufflators, which are relatively new in clinical practice, will be used under low intra-abdominal pressure throughout the surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valveless Insufflator with 8 mmHg intra-abdominal pressure
Description: In this group valveless insufflators, which are relatively new in clinical practice, will be used under ultra-low intra-abdominal pressure throughout the surgery.
Study: NCT05244187

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoCor Active System
Description: The OrthoCor Active System is a portable (battery operated) non-invasive device that delivers Pulsed Electromagnetic Field (PEMF) therapy for General Use of temporary pain relief, utilizing wraps that position the therapy, such as on the ankle, back, knee, wrist, elbow, shoulder, foot, or neck.
Study: NCT06391242

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Conventional Radiotherapy
Description: 20Gy in 5 fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: 30 or 35Gy in 5 fractions
Study: NCT06022679

Intervention type: OTHER
Intervention: CBCT
Description: CBCT examination in supine position A computerized 3D-analysis using Dolphin Imaging 11.95 software was performed in each CBCT.

Intervention type: OTHER
Intervention: CBCT
Description: CBCT examination in supine position A computerized 3D-analysis using Dolphin Imaging 11.95 software was performed in each CBCT.
Study: NCT05439837

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infraclavicular and subomohoid block
Description: Its blockade of subscapular nerve in the subscapular fossa and axillary nerve as it curves around humeral And blocking of brachial plexuses cord and supra scapular nerve And blocking of the brachial plexuses cord and supra scapular nerve

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paracoracoid subscapularis plane block
Description: Blocking of suprascapular nerve in supra scapular fossa and axillary nerve as it curves the humeral head
Study: NCT05243316

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clamping
Description: There will be a randomized selection of patients who will have a clamping of the chest tube 6 hours prior to chest tube removal.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Non Clampling
Description: There will be a randomized selection of patients who wont have chest tube clamping 6 hours prior to chest tube removal.
Study: NCT06358885

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facilitation (FAC)
Description: The facilitation approach will use a flexible clinic level implementation strategy that helps clinics to address common barriers, such as counselor skills, competing priorities, and resource deficits.
Study: NCT06366919

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Alexander Technique (AT)
Description: The AT arm of study will involve participants receiving indivisual sessions. These sessions will typically focus on non specific neck pain management improving posture , movement coordination and body awareness through gentle hands on guidance

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Feldenkrais Technique (FT)
Description: The FT arm of study will involve participants recieving individual sessions. These sessions will typically focus on pain improvement, maintaining alignment, reducing muscle tension and promoting ease of movement.
Study: NCT05972889

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NexWave
Description: Device subjects receive designated treatment mode twice daily for up to 8 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NexWave
Description: Device subjects receive designated treatment mode twice daily for up to 8 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham subjects provided with Sham Device and treatment instructions identical to that of NexWave Device Arm for their designated Sham Arm. Sham subjects participate for 4 weeks with the option to crossover to the NexWave Device Arm for an additional 4 weeks (up to 8 weeks total).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham subjects provided with Sham Device and treatment instructions identical to that of NexWave Device Arm for their designated Sham Arm. Sham subjects participate for 4 weeks with the option to crossover to the NexWave Device Arm for an additional 4 weeks (up to 8 weeks total).
Study: NCT04739774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF6001 DPI
Description: Single dose of CHF6001
Study: NCT06342375

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outbound phone call
Description: Participants will receive either a live or pre-recorded outbound phone call

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outbound phone call
Description: Participants will receive either a live or pre-recorded outbound phone call
Study: NCT05419830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BBTI
Description: Participants randomized to BBTI will receive 45- to 60-minute individual intervention session followed by a 30-minute follow-up session 2 weeks later, and 20-minute telephone calls after 1 and 3 weeks. BBTI will focus on four behaviors that promote sleep and discussion of homeostatic and circadian mechanisms of human sleep regulation. These four interventions are simple to conceptualize and implement, and constitute the core of efficacious multi-modal behavioral treatments for insomnia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PM antihypertensive dosing or Chronotherapy
Description: participants will be asked to switch their conventional once daily non-diuretic antihypertensive to bedtime

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AM antihypertensive dosing
Description: participants will be asked to continue taking their antihypertensive medication within an hour of awakening
Study: NCT06373588

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigator
Description: The patient navigator will meet the following requirements: a bachelor's degree in health or social sciences, or equivalent experiences; strong knowledge of the local health and social services system; trauma-informed care and cultural safety; strong interpersonal skills, ability to problem-solve, and autonomy; have prior experiences with migrant communities (including lived experiences) and working in healthcare setting. The navigator will be trained on topics related to their role, through case discussions, and role playing, as done in other navigator trials. Topics will include Indigenous cultural safety as applied to migrant health, systems navigation, care coordination, family-centred care, social determinants of health (health insurance, income supplements, etc.) and inequities, advanced communication and helping skills (e.g., motivational interviewing), ethics, privacy, and confidentiality, and others as determined through our co-design process.
Study: NCT06482892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP03HN106
Description: During the dose escalation phase, subjects will undergo a dose escalation trial of intravenous injection of TP03HN106 for 5 consecutive days to evaluate the safety and tolerance of the subjects to the injection dose of TP03HN106. The preset initial dose for this experiment is 10U/kg, with gradient doses of 20, 30, 40, and 50U/kg. Observe the subjects receiving the investigational drug for any adverse events (AEs) after daily intravenous injection.~During the maintenance treatment phase, the subjects will undergo two consecutive treatment courses at the final dose during the dose escalation phase. During each treatment course, subjects will complete the collection of efficacy and safety data for 14 consecutive days of medication (administered every 2 days) and 14 days of discontinuation to evaluate the efficacy and safety of TP03HN106 for subjects with critical limb ischemia.
Study: NCT04729283

Intervention type: PROCEDURE
Intervention: Sigmoidectomy
Description: The sigmoid resection surgery, realized by laparoscopy or laparotomy, with anastomosis.

Intervention type: PROCEDURE
Intervention: Sigmoidectomy
Description: The sigmoid resection surgery, realized by laparoscopy or laparotomy, with anastomosis.
Study: NCT05203835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acebilustat
Description: By mouth, once a day, 100 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match acebilustat by mouth, once a day
Study: NCT04758208

Intervention type: DIAGNOSTIC_TEST
Intervention: Hematology Parameters
Description: Measurement of hematology parameters on BC-6800Plus
Study: NCT06328920

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube Feeding
Description: The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube Feeding
Description: The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time.
Study: NCT06358885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facilitation (FAC)
Description: The facilitation approach will use a flexible clinic level implementation strategy that helps clinics to address common barriers, such as counselor skills, competing priorities, and resource deficits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experiential Brief Alcohol Intervention (EBAI)
Description: Clinic staff will be offered the experiential BAI prior to implementation. The BAI comprises 2 in-person sessions and 2 booster phone sessions. Clinic staff responsible for delivering the BAI to PWH participants will be offered 3 additional consolidation sessions to integrate their experiences receiving the BAI with their delivery of the BAI.
Study: NCT05592223

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCG Vaccine USP
Description: 2x10\^6 cfu Tice® BCG (ID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BCG Vaccine USP
Description: 2x10\^6 cfu Tice® BCG (ID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCG Vaccine USP
Description: 2x10\^6 cfu Tice® BCG (ID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: INH in the dose of 300 mg for three days post BCG injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: RIF in the dose of 600 mg for seven days post BCG injection.
Study: NCT05278858

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MedJet Device with intralesional triamcinolone
Description: A standard sterile disposable 5 ml syringe will be used to draw TAC using standard sterile protocol. This syringe will be attached to the Med-Jet along with a sterile barrel and disposable sterile tip. The target lesion will be wiped with alcohol and injected with 10mg/ml of TAC directed towards the dermis to create a blanching wheal that is 1 cubic centimeter (total of 0.1 ml of injected fluid). The optimal injection pressure used on the subject will start at 110 pounds per square inch (psi) and increased by 10 psi until a blanching wheal is observed. The optimal pressure will be recorded. The injections will be repeated multiple times at the optimal pressure until the targeted patch is completely treated.
Study: NCT04865120

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cream cyclic merocyanine
Description: cream long-UVA absorber
Study: NCT04804956

Intervention type: PROCEDURE
Intervention: Stool sample
Description: One stool sample will be taken at baseline for microbiota characterization

Intervention type: PROCEDURE
Intervention: Stool sample
Description: One stool sample will be taken at baseline for microbiota characterization

Intervention type: PROCEDURE
Intervention: Stool sample
Description: One stool sample will be taken at baseline for microbiota characterization

Intervention type: PROCEDURE
Intervention: Rectal mucosa sample
Description: Characterization of tissue microbiota before and after surgery.

Intervention type: PROCEDURE
Intervention: Rectal mucosa sample
Description: Characterization of tissue microbiota before and after surgery.

Intervention type: PROCEDURE
Intervention: Rectal mucosa sample
Description: Characterization of tissue microbiota before and after surgery.

Intervention type: PROCEDURE
Intervention: Mesorectal adipose tissue sample
Description: Characterization of tissue microbiota and dysfunction

Intervention type: PROCEDURE
Intervention: Mesorectal adipose tissue sample
Description: Characterization of tissue microbiota and dysfunction

Intervention type: PROCEDURE
Intervention: Mesorectal adipose tissue sample
Description: Characterization of tissue microbiota and dysfunction

Intervention type: PROCEDURE
Intervention: Subcutaneous adipose tissue sample
Description: Characterization of tissue microbiota and dysfunction

Intervention type: PROCEDURE
Intervention: Subcutaneous adipose tissue sample
Description: Characterization of tissue microbiota and dysfunction

Intervention type: PROCEDURE
Intervention: Subcutaneous adipose tissue sample
Description: Characterization of tissue microbiota and dysfunction
Study: NCT04739774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Repeated doses of oral Itraconazole
Study: NCT04804956

Intervention type: PROCEDURE
Intervention: Visceral adipose tissue sample
Description: Characterization of tissue microbiota and dysfunction

Intervention type: PROCEDURE
Intervention: Visceral adipose tissue sample
Description: Characterization of tissue microbiota and dysfunction

Intervention type: PROCEDURE
Intervention: Visceral adipose tissue sample
Description: Characterization of tissue microbiota and dysfunction
Study: NCT06467656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized, periodized endurance training for ultra-endurance triathlon.
Description: Endurance exercise consisting of swimming, cycling and running training for a minimum of 3 hours /week up to a maximum of 20 hours/week with regular rest days and intensities being fluctuated throughout the program to optimize training stimulus and adaptation. Strengthening exercises to complement the aerobic training, enhance conditioning and prevent injury will also be performed 1-2 hours/week for the first 9-months of the program.
Study: NCT04563442

Intervention type: OTHER
Intervention: complication
Description: complication co morbidities
Study: NCT04804956

Intervention type: BEHAVIORAL
Intervention: Dietary assessment
Description: Dietary assessment will be taken at baseline

Intervention type: BEHAVIORAL
Intervention: Dietary assessment
Description: Dietary assessment will be taken at baseline

Intervention type: BEHAVIORAL
Intervention: Dietary assessment
Description: Dietary assessment will be taken at baseline
Study: NCT06467656

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Time-Aligned Control
Description: Participants will receive no specific intervention and will continue to live their lives as if they were not in a study.
Study: NCT06043765

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real repetitive transcranial magnetic stimulation (rTMS)
Description: real rTMS -- 3 sessions a week/7 weeks (21 sessions)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham repetitive transcranial magnetic stimulation (rTMS)
Description: sham rTMS - 3 sessions a week/7 weeks (21 sessions)
Study: NCT06184308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Physical Rehabilitation
Description: Six out of seven days a week, gentle flexibility practice (upper arm and shoulder movements) that can be done seated or standing and two slow walking sessions focused on balance. In addition, complete a breathing practice focused on breathing in through the nose and exhaling through the mouth.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: Study-trained nurse whom utilizes participant data to guide interactions in weekly calls.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: Study-trained nurse whom utilizes participant data to guide interactions in weekly calls.
Study: NCT05216601

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVC-COV1901
Description: Approximately 40 participants who previously completed two (Group A) or three (Group B) doses of MVC-COV1901 will receive 1 doses of MVC-COV1901 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region. Group A and B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVC-COV1901(Beta)-15
Description: Approximately 40 participants who previously completed two (Group A) or three (Group B) doses of MVC-COV1901 will receive 1 doses of MVC-COV1901(Beta)-15 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVC-COV1901(Beta)-25
Description: Approximately 40 participants who previously completed two (Group A) or three (Group B) doses of MVC-COV1901 will receive 1 doses of MVC-COV1901(Beta)-25 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region
Study: NCT01179035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transitions Clinic - parolee-targeted care
Description: Subjects receive ongoing primary care from the Transitions Clinic versus ongoing primary care in the San Francisco Department of Public Health affiliated primary care network.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expedited Primary Care
Description: Following randomization, subjects receive ongoing primary care in the San Francisco Department of Public Health affiliated primary care network. Appointments are expedited with safety-net primary care providers.
Study: NCT05967897

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberries
Description: 22 g freeze-dried blueberry powder mixed with water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Blueberries and Whey Protein
Description: 22 g freeze-dried blueberry powder mixed with whey protein and water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Blueberries and Pea Protein
Description: 22 g freeze-dried blueberry powder mixed with pea protein and water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Blueberries and Hemp Protein
Description: 22 g freeze-dried blueberry powder mixed with hemp protein and water
Study: NCT04865120

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT05405387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide EC
Description: Subjects will take 3mg of Budesonide or placebo. Dosing will begin on day prior to cell infusion and continue until Day 14 post transplant. Budesonide or placebo will be in capsule formulation. Budesonide or Placebo will be administered orally three times daily (every 8 hours ± 1 hours) with or without food.
Study: NCT06256562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR18
Description: Titrated to dose 1, dose 2, dose 3 or dose 4
Study: NCT05405387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide EC
Description: Subjects will take 3mg of Budesonide or placebo. Dosing will begin on day prior to cell infusion and continue until Day 14 post transplant. Budesonide or placebo will be in capsule formulation. Budesonide or Placebo will be administered orally three times daily (every 8 hours ± 1 hours) with or without food.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take 3mg of Budesonide or placebo. Dosing will begin on day prior to cell infusion and continue until Day 14 post transplant. Budesonide or placebo will be in capsule formulation. Budesonide or Placebo will be administered orally three times daily (every 8 hours ± 1 hours) with or without food.
Study: NCT06250166

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iPLANT diet plan and diet counselling
Description: A diet plan which mainly consists of plant-based food will be designed based on participants' energy and protein needs. The counselling covers (1) guidance to achieve energy and protein requirement (2) advice on food to be included in iPLANT diet plan (Mediterranean diet: increase intake of fish and legumes; moderate intake of eggs, dairy, nuts, poultry; limit intake of red meat).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual diet counselling
Description: General dietary advices on how to improve oral intake and maintain healthy weight will be provided.
Study: NCT06256562

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered the same volume as GZR18
Study: NCT06043765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive strategy training
Description: 7 weekly sessions with a trained neuropsychologist.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: cognitive strategy training
Description: 7 weekly sessions with a trained neuropsychologist.
Study: NCT06223009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cNP8
Description: cNP8 for injection is provided as a sterile lyophilizate for solution for infusion. Subjects will receive a single 30 minute IV infusion of cNP8 at their assigned dose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects not randomized to cNP8 will receive a single 30 minute IV infusion of placebo.
Study: NCT04879732

Intervention type: DEVICE
Group type: OTHER
Intervention: ACTIS
Description: ACTIS Hip stem